The NIH's role in accelerating translational sciences

John C. Reed; E. Lucile White; Jeffrey Aub́; Craig Lindsley; Min Li; Larry Sklar; Stuart Schreiber

doi:10.1038/nbt.2087

The NIH's role in accelerating translational sciences

John C. Reed, E. Lucile White, Jeffrey Aub́, Craig Lindsley, Min Li, Larry Sklar, Stuart Schreiber

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	16-19
Number of pages	4
Journal	Nature biotechnology
Volume	30
Issue number	1
DOIs	https://doi.org/10.1038/nbt.2087
State	Published - Jan 2012

ASJC Scopus subject areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
Molecular Medicine
Biomedical Engineering

Access to Document

10.1038/nbt.2087

Cite this

@article{ba7b8be6ddb74795956d23364467173f,

title = "The NIH's role in accelerating translational sciences",

author = "Reed, {John C.} and White, {E. Lucile} and Jeffrey Au{\'b} and Craig Lindsley and Min Li and Larry Sklar and Stuart Schreiber",

note = "Funding Information: The proposed plan for NCATS, which was devised with input from a broad spectrum of knowledgeable stakeholders1, aims to solidify and expand NIH{\textquoteright}s commitment to improving the efficiency with which its investment in basic research is translated into improvements in human health. Nearly all of the programs slated to move into NCATS are already funded by NIH2, through the NIH Center for Research Resources, the NIH Common Fund or the Office of the Director. Importantly, much of what NCATS will support provides a basic infrastructure for America{\textquoteright}s nonprofit life sciences research community to enable translation of basic research into clinical impact, including such programs as the (i) Clinical and Translational Science Awards (CTSA; https://www.ctsacentral. org/), which provide a broad spectrum of services and organizational capabilities for fostering translational and clinical research at 60 of the nation{\textquoteright}s medical schools; (ii) the Molecular Libraries Program (MLP), which provides essential infrastructure for small-molecule drug discovery, making sophisticated services available in assay development, high-throughput screening, large chemical libraries, cheminformatics and medicinal chemistry (http://mli.nih.gov/mli/); and (iii) Therapeutics for Rare & Neglected Diseases, devoted to nurturing promising therapies for rare and neglected diseases through preclinical development and into clinical testing (http://trnd.nih.gov/). Here we describe what we see as the feasibility, opportunities, possible pitfalls and potential impact of NCATS. Copyright: Copyright 2012 Elsevier B.V., All rights reserved.",

year = "2012",

month = jan,

doi = "10.1038/nbt.2087",

language = "English (US)",

volume = "30",

pages = "16--19",

journal = "Biotechnology",

issn = "1087-0156",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - The NIH's role in accelerating translational sciences

AU - Reed, John C.

AU - White, E. Lucile

AU - Aub́, Jeffrey

AU - Lindsley, Craig

AU - Li, Min

AU - Sklar, Larry

AU - Schreiber, Stuart

N1 - Funding Information: The proposed plan for NCATS, which was devised with input from a broad spectrum of knowledgeable stakeholders1, aims to solidify and expand NIH’s commitment to improving the efficiency with which its investment in basic research is translated into improvements in human health. Nearly all of the programs slated to move into NCATS are already funded by NIH2, through the NIH Center for Research Resources, the NIH Common Fund or the Office of the Director. Importantly, much of what NCATS will support provides a basic infrastructure for America’s nonprofit life sciences research community to enable translation of basic research into clinical impact, including such programs as the (i) Clinical and Translational Science Awards (CTSA; https://www.ctsacentral. org/), which provide a broad spectrum of services and organizational capabilities for fostering translational and clinical research at 60 of the nation’s medical schools; (ii) the Molecular Libraries Program (MLP), which provides essential infrastructure for small-molecule drug discovery, making sophisticated services available in assay development, high-throughput screening, large chemical libraries, cheminformatics and medicinal chemistry (http://mli.nih.gov/mli/); and (iii) Therapeutics for Rare & Neglected Diseases, devoted to nurturing promising therapies for rare and neglected diseases through preclinical development and into clinical testing (http://trnd.nih.gov/). Here we describe what we see as the feasibility, opportunities, possible pitfalls and potential impact of NCATS. Copyright: Copyright 2012 Elsevier B.V., All rights reserved.

PY - 2012/1

Y1 - 2012/1

UR - http://www.scopus.com/inward/record.url?scp=84862912729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862912729&partnerID=8YFLogxK

U2 - 10.1038/nbt.2087

DO - 10.1038/nbt.2087

M3 - Comment/debate

C2 - 22231085

AN - SCOPUS:84862912729

VL - 30

SP - 16

EP - 19

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 1

ER -

The NIH's role in accelerating translational sciences

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this